Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo


Newell P., Toffanin S., Villanueva A., Chiang D. Y., Minguez B., Cabellos L., ...More

JOURNAL OF HEPATOLOGY, vol.51, no.4, pp.725-733, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 4
  • Publication Date: 2009
  • Doi Number: 10.1016/j.jhep.2009.03.028
  • Journal Name: JOURNAL OF HEPATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.725-733
  • Keywords: Liver cancer, HCV, Signaling pathway, Molecular therapies, Ras, mTOR, PROMOTER HYPERMETHYLATION, MOLECULAR CLASSIFICATION, ABERRANT METHYLATION, SIGNALING PATHWAYS, HIGH-FREQUENCY, SUPPRESSOR, RASSF1A, GENE, NORE1A, INACTIVATION
  • Erciyes University Affiliated: Yes

Abstract

Background/Aims: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.